Ascendia

  MARKET NEWS

Gradalis Secures FDA Regenerative Medicine Advanced Therapy Designation for Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
Indaptus Therapeutics Receives Approval From Health Canada to Expand Clinical Trial of Decoy20
Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
Quantum Biopharma Announces the Success of unbuzzd Clinical Trial
Gelteq Launches SportsGel Brand & Signs Distribution Agreement With E-Commerce Solutions Company
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility From Catalent & Expands Bioanalytical Services in North America
Northstrive Biosciences Reports Positive Updates for Obesity Drug Candidates
BioNTech Completes Acquisition of Biotheus
Purple Biotech Announces Research Collaboration With the Icahn School of Medicine at Mount Sinai
HCW Biologics Granted FDA Clearance to Evaluate One of its Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

  EXPERT CONTENT & RESOURCES

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.  

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.

ALBA SUCCESS CASE

Container Selection for a Highly Sensitive Drug Product: A Success Story

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.

  FEATURED EDITORIAL

  COMPANY PROFILE

Thermo Fisher Scientific is the world leader in serving science, empowering customers to make the world healthier, cleaner, and safer. We accelerate life sciences research, solve analytical challenges, enhance lab productivity, improve patient health, and develop life-changing therapies. Our global team delivers innovative technologies and pharmaceutical services through trusted brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 12 – Injection Devices
February 19 – Formulation Development